Get started

Winicker Norimed GmbH (Germany)

Alternate names: Winicker Norimed, Winicker Norimed GmbH, Winicker Norimed Medizinische Forschung GmbH, Winicker-Norimed GmbH Medizinische Forschung
ROR: 05aeq8963
OpenAlex ID: I4405267994
Efficacy of artichoke leaf extract in the treatment of patients with functional dyspepsia: a six‐week placebo‐controlled, double‐blind, multicentre trial
2003 · G. Holtmann, B. Adam, et al. · Alimentary Pharmacology & Therapeutics · 151
PDF
Use of Fondaparinux Off-Label or Approved Anticoagulants for Management of Heparin-Induced Thrombocytopenia
2017 · Marc Schindewolf, Julia Steindl, et al. · Journal of the American College of Cardiology · 75
PDF
Effects of Pumpkin Seed in Men with Lower Urinary Tract Symptoms due to Benign Prostatic Hyperplasia in the One-Year, Randomized, Placebo-Controlled GRANU Study
2014 · Winfried Vahlensieck, Christoph Theurer, et al. · Urologia Internationalis · 72
Low dose estriol pessaries for the treatment of vaginal atrophy: A double-blind placebo-controlled trial investigating the efficacy of pessaries containing 0.2 mg and 0.03 mg estriol
2012 · Henrik Griesser, Stefan Skonietzki, et al. · Maturitas · 63
Ethinylestradiol 20 versus 30 μg combined with 150 μg desogestrel: a large comparative study of the effects of two low-dose oral contraceptives on the hemostatic system
1996 · U. H. Winklev, T. Hölscher, et al. · Gynecological Endocrinology · 28
Influence of salmeterol/fluticasone via single versus separate inhalers on exacerbations in severe/very severe COPD
2013 · Cordula Hagedorn, Frank Kässner, et al. · Respiratory Medicine · 18
Is there an association between social determinants and care dependency risk? A multi‐state model analysis of a longitudinal study
2020 · Alice Schneider, Stefan Blüher, et al. · Research in Nursing & Health · 15
PDF
BAY 81‐8973, a full‐length recombinant factor VIII : results from an International comparative laboratory field study
2016 · S. Kitchen, H. Beckmann, et al. · Haemophilia · 15
PDF
Cladistic Analysis of Paleo-island Populations of the Florida Harvester Ant (hymenoptera: Formicidae) Based Upon Divergence of Mitochondrial Dna Sequences
2004 · Christoph-Peter Strehl, Jürgen Gadau · Florida Entomologist · 12
PDF
SAfety of Fondaparinux in transoesophageal echocardiography-guided Electric cardioversion of Atrial Fibrillation (SAFE-AF) study: A pilot study
2014 · Ariel Cohen, Christoph Stellbrink, et al. · Archives of cardiovascular diseases · 9
Physical activity levels are positively related to progression-free survival and reduced adverse events in advanced ER+ breast cancer
2024 · Philipp Zimmer, Tobias Esser, et al. · BMC Medicine · 8
PDF
Sunitinib for Metastatic Renal Cell Carcinoma: Real-World Data from the STAR-TOR Registry and Detailed Literature Review
2024 · Annemarie Uhlig, Lothar Bergmann, et al. · Urologia Internationalis · 7
Conditional progression-free survival in patients with metastatic hormone receptor-positive, human epidermal growth factor receptor 2-negative breast cancer treated with first-line ribociclib and endocrine therapy: real-world data from the RIBANNA study
2025 · T. Decker, C. Brucker, et al. · ESMO Open · 6
PDF
Die ambulante Therapie der akuten tiefen Beinvenenthrombose
2001 · M Offermann, J Koepchen, et al. · DMW - Deutsche Medizinische Wochenschrift · 5
Efficacy and safety of everolimus plus exemestane in patients with hormone receptor‐positive, HER ‐2‐negative advanced breast cancer: Results from the open‐label, multicentre, non‐interventional BRAWO study
2024 · Diana Lüftner, Florian Schuetz, et al. · International Journal of Cancer · 4
PDF
Retrospective Analysis of Treatment Pathways in Patients With BRAFV600E-mutant Metastatic Colorectal Carcinoma – MORSECRC
2022 · ARMIN GERGER, WOLFGANG EISTERER, et al. · Anticancer Research · 4
PDF
Analysis of everolimus starting dose as prognostic marker in HR+ mBC patients treated with everolimus (EVE) + exemestane (EXE): Results of the 3rd interim analysis of the non-interventional trial BRAWO.
2017 · Peter A. Fasching, Eva-Maria Grischke, et al. · Journal of Clinical Oncology · 4
Abstract P4-01-01: RIBANNA 5th interim analysis: Matched-pair analysis of progression-free survival (PFS) across treatment cohorts and comparison of frontline ribociclib + endocrine therapy PFS data from RIBANNA vs MONALEESA trials, in HR+, HER2– ABC
2023 · Christian Jackisch, Cosima Brucker, et al. · Cancer Research · 3
Abstract P4-01-03: Progression-free survival and patient-reported outcomes in HR+, HER2– ABC patients treated with first-line ribociclib + endocrine therapy (ET) or ET monotherapy or chemotherapy in real world setting: 5th interim analysis of RIBANNA
2023 · Peter A. Fasching, Cosima Brucker, et al. · Cancer Research · 3
Inclisiran vs bempedoic acid for low-density lipoprotein cholesterol lowering in high-risk patients: the VICTORION-challenge trial
2026 · Ingo Hilgendorf, Dirk Westermann, et al. · European Heart Journal · 2
PDF
338P Real-world progression-free survival (PFS) and overall survival (OS) for advanced breast cancer (aBC) treated with ribociclib (RIB) in the RIBANNA trial
2025 · A. Woeckel, C. Brucker, et al. · ESMO Open · 2
Axitinib beyond first-line therapy of Metastatic Renal Cell Carcinoma: Real World Data from the STAR-TOR registry
2023 · Annemarie Uhlig, Johannes Uhlig, et al. · Kidney Cancer · 2
PDF
Real‐world progression‐free survival and overall survival in patients with HR + / HER2 − advanced breast cancer treated in first‐line with ribociclib, endocrine monotherapy or chemotherapy: Results from the observational RIBANNA study
2026 · Peter A. Fasching, Cosima Brucker, et al. · International Journal of Cancer · 1
Real-world efficacy of ribociclib (RIB) + aromatase inhibitor (AI)/fulvestrant (FUL), or endocrine monotherapy (ET), or chemotherapy (CT) as first-line (1L) treatment (tx) in elderly patients (pts; > 75 years) with hormone receptor–positive (HR+), human epidermal growth factor receptor-2–negative (HER2–) advanced breast cancer (ABC): Results of fifth interim analysis (IA) from RIBANNA.
2023 · Thomas Decker, Cosima Brucker, et al. · Journal of Clinical Oncology · 1
Effect of antacid intake on the therapeutic efficacy of sunitinib (SUN) in metastatic renal cell carcinoma (mRCC) patients (pts): A sub-analysis of the STAR-TOR registry
2019 · K. Schlack, M. Boegemann, et al. · Annals of Oncology · 1
PDF
Works count: 36
Citation count: 1,089
Year
Topic
Type